Category: Uncategorized

^{Driving Innovation: Bolt.Earth and Chinv Redefine the Future of Electric Mobility at EICMA 2023 (Graphic: Business Wire)}

Drive Smart. Ride Connected. The Future of E-Mobility is Unfolding

SINGAPORE, Nov 3 (Bernama-BUSINESS WIRE) — Bolt.Earth, a Singapore-based pioneer in the connected EV Operating System market, further strengthens its partnership with Chinv, the renowned designer and manufacturer of EV 2-wheeler bikes. Together, they are set to redefine the future of electric mobility at this year’s EICMA 2023 at Fiera Milano-Rho Milan. Witness the synergy of Chinv’s design mastery and Bolt.Earth’s smart operating stack, merging years of collaborative effort to produce an EV experience like no other.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231101137680/en/

Building on their longstanding collaboration, the unveiling of the new Bolt.Earth Blaze at EICMA 2023 is anticipated to mark a pivotal moment in the global EV landscape. Bolt.Earth Blaze is a fast-charging platform conceived to redefine the EV charging paradigm. This innovation significantly trims charging durations, making electric mobility more expedient and accessible.

Jyotiranjan Harichandan, Co-Founder at Bolt.Earth, remarked, “Our journey with Chinv has been truly transformative. This partnership, built on a mutual vision and relentless innovation, is about redefining sustainable transport. Chinv’s exceptional experience in hardware design & development, combined with our charging and vehicle operating stack, is laying the groundwork for the future.”

The convergence of Bolt.Earth’s advanced software solutions and Chinv’s hardware design and development expertise signals a transformative phase for sustainable transportation. This venture aims to elevate electric vehicles, ensuring they are environmentally responsible and technologically superior.

Ms. Xu Duo (Rita), President of Chinv expressed, “Our alliance with Bolt.Earth represents a bold step towards a smarter, more sustainable horizon. The potential to revolutionize the EV sphere is immense, and together, we are poised to lead this change.”

Join us at EICMA 2023, held from November 7th to November 12th at Fiera Milano-Rho Milan, where Bolt.Earth will be showcasing their latest offerings at booth number C-49 in Hall Number 14, in association with Chinv along with an amazing virtual reality experience.

About Chinv

Chinv, founded in Hong Kong in 2006, operates under multiple brands, including “OKLA” for electric vehicles, “Motrac” for gasoline vehicles, “O-Town” for clothing, “OKLATEC” for R&D and “CHINV” for lights and electric parts; redefining the way we move and setting new standards for eco-friendly mobility, with a vision to drive positive change and a goal to develop cleaner and more efficient transportation solutions.

OKLATEC has R&D experience in designing over 50 motorcycles, ranging (from ICE to EV), for customers worldwide. Building on these milestones, Chinv has been successful in supporting the launch of multiple brands at various integration levels for both electrical and mechanical aspects, covering a wide range from low-speed to high-performance EV motorcycles. As a result, Chinv has become a one-stop solution in the EV motorcycle supply chain.

About Bolt.Earth

Bolt.Earth is on a mission to push emerging markets toward cleaner mobility. The company deploys state-of-the-art embedded smart speedometer clusters that redefine your EV riding experiences. Designed for safety and convenience, Bolt.Earth’s speedometer clusters and display units use Bolt.Earth’s OS to provide vehicle management tools, crucial data, anti-theft precautions, and customization options for a smart, connected & modern riding experience. Additionally, Bolt.Earth enables India’s largest peer-to-peer EV charging network, with 30,000+ charging points across 1,100 cities. They offer charging solutions for individuals, businesses, real estate companies, fleet operators, and the government. For more information about their solutions, visit bolt.earth.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20231101137680/en/

Contact

Media Contact: marketing@bolt.earth

Source : Bolt.Earth

MALVERN, Pa. & CHONGQING, China, Nov 2 (Bernama-BUSINESS WIRE) — Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs.

“The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” said Resolian CEO Patrick Bennett. “Denali’s founders and core scientists are internationally recognized across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services. We look forward to leveraging our growing company’s strengths to continue driving innovation and creating lasting value for our clients and stakeholders.”

“The Denali team is thrilled to join Resolian,” said Denali CEO Min Meng, Ph.D. “Denali was founded by a group of U.S.-trained bioanalytical experts in a state-of-the-art lab facility in China to provide exceptional service for domestic and international clients. We look forward to continuing this track record and offering even greater capabilities and trial flexibility as part of Resolian.”

About Resolian

Resolian (formerly Alliance Pharma Inc. and Drug Development Solutions Ltd.) is a leading global research laboratory that provides specialized services in GxP and nonregulated bioanalysis, drug metabolism/pharmacokinetics (DMPK), and GMP CMC analytical and materials science. Over 500 experts across the U.S., U.K., China, and Australia deliver quality results, ensuring the highest standard of regulatory compliance throughout the drug development continuum. Resolian’s dedicated laboratories are equipped with state-of-the-art technology that meet the needs of preclinical and clinical programs at any scale.

About Denali Medpharma

Denali is a China based bioanalytical CRO, now part of Resolian Bioanalytics. With 70 full-time employees, its core leadership have extensive working experience in the U.S. and China CRO industry. It is equipped with the world’s most advanced instruments. Denali’s quality assurance system is established in strict accordance with domestic and foreign laws and regulations related to bioanalysis. Denali is well known as the industry leader in China in the bioanalysis of oligonucleotide drugs and mRNA vaccines (PK/PD and ADA), liposomal drug (free and encapsulated drug), ultra-sensitive assays for inhalation drugs, and biomarker assays, etc.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20231101490232/en/

Contact

Lindsey Langemeier
SCORR Marketing
+1 402-405-4269
lindsey@scorrmarketing.com

Source : Resolian

RIYADH, Saudi Arabia, Nov 1 (Bernama-GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) has achieved a significant milestone by successfully conducting liquid biopsies on patients spanning various age groups. This innovative approach offers a safer alternative to conventional tissue biopsies. Notably, KFSH&RC stands out as the first healthcare facility in the Middle East to adopt this cutting-edge technology. 

This groundbreaking method is distinguished by its ability to detect approximately 50 genes associated with cancer and over 3,000 genetic mutations. This represents a pivotal advancement in patient care, eliminating the need to extract tissue from the affected area for examination. This transformative step greatly enhances healthcare outcomes and elevates the overall patient experience.

Liquid biopsy offers advantages over traditional tissue biopsies. It’s less invasive, involving a simple 10 ml blood sample that can be repeated during treatment. Additionally, it provides high accuracy in swiftly detecting tumor biomarkers, predicting treatment responses, identifying emerging mutations, and confirming the absence of tumor recurrence, marking a significant advancement in cancer science.

This technology presents a safer alternative to traditional biopsies for patients facing challenges in accessing affected tissue without surgical intervention, as seen in cases like lung cancer. It is particularly beneficial for elderly patients, for whom a lung tissue biopsy may not be suitable due to the potential for severe complications associated with it.

As a strategic health partner at the Global Health Exhibition in Riyadh from October 29 to 31, KFSH&RC will showcase its pavilion in the accompanying exhibition, where visitors can explore Liquid biopsy technology and various other healthcare solutions and technologies.

Liquid biopsy technology holds promise for other stages of cancer treatment at KFSH&RC. Through the routine use of the test, it is possible to build a database of tumor-causing mutations in the local community, which helps in early diagnosis of cancer before tumors form, in addition to tracking changes in the patient’s condition, frequently during treatment, allowing timely adjustments to treatment plans and preventing worsening of the condition.

This achievement is a part of KFSH&RC’s ongoing commitment to harness advanced technologies for enhancing operational excellence and patient care. The test facilitates swift clinical decision-making for cancer patient management and reduces both the testing time and its process through full automation.

KFSH&RC stands as one of the world’s prominent institutions in delivering specialized healthcare, leading the way in innovation, and serving as an advanced hub for medical research and education. Furthermore, it actively endeavors to advance medical technologies and elevate global healthcare standards through collaborations with significant local, regional, and international organizations, aiming to deliver world-class clinical, research, and educational services.

Contact information:
kfshrc@mcsaatchi.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/3ba7a2cd-ae09-4d9a-8658-a5efc2b198c3

https://www.globenewswire.com/NewsRoom/AttachmentNg/9de0dc61-7dc5-47e4-af70-09088ad689e1

Source: King Faisal Specialist Hospital & Research Centre

–BERNAMA

KUALA LUMPUR, Oct 31 (Bernama) — The King Faisal Specialist Hospital and Research Centre (KFSH&RC) celebrated its success in treating the 100th patient with lymphoid leukaemia using Chimeric Antigen Receptor T-cell (CAR T-cell) therapy, aligned with its vision to be the optimal choice for specialised healthcare.

CAR T-cell therapy is an innovative treatment that enhances the ability of T-cells to recognise and destroy cancer cells after genetic modification in the laboratory to improve their targeting ability.

According to a statement, this approach overcomes the challenge of distinguishing between cancer and normal cells, offering a promising method for treating lymphoid leukaemia.

KFSH&RC emphasised that this innovative technology provides hope for patients with resistant leukaemia and lymphoid tumours, especially those not effectively treatable with traditional methods.

As a strategic healthcare partner, the hospital is sharing information about CAR T-cell therapy, its positive impact on healthcare improvement, and various healthcare solutions and innovations during the Global Health Exhibition taking place in Riyadh from Oct 29 to 31.

The hospital explained that this advanced therapy consists of four stages, namely, extracting blood from the patient to obtain specific cells; and then genetically modifying them in the lab for three to four weeks.

Next, shortly before CAR T-cell therapy, the patient receives a low dose of chemotherapy to enhance its effectiveness and the body’s ability to fight cancer. Ultimately, CAR T-cells are infused into the patient’s arm, which is closely monitored for four weeks to ensure the body’s adaptation.

The application of this advanced treatment in the Kingdom represents a qualitative addition to specialised medical care, reducing the financial, social and health burdens of sending such cases abroad, aligning with Saudi Vision 2030 and its healthcare objectives.

— BERNAMA

RIYADH, Saudi Arabia, Oct 30 (Bernama-GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) is presenting its pioneering journey and prospects in space biomedical research and its role in enhancing human health at the Global Health Exhibition, where KFSH&RC is also participating as a strategic healthcare partner.

At the Exhibition, KFSH&RC delves into its groundbreaking experience leading four research experiments in cell sciences in space. These experiments encompass testing the immune cell response to inflammation in space, monitoring the activity of thousands of genes in immune cells exposed to inflammation over time, and tracking the changes in the lifespan of ribonucleic acid (mRNA) between space and Earth. Additionally, the pavilion simulates the inflammatory response to drug treatment using an immune cell model to explore its potential applications for prevention and early treatment.

The aim of these research experiments, conducted in collaboration with the Saudi Space Authority, as part of the scientific mission of Saudi astronauts Rayyanah Barnawi and Ali Al-Qarni to the International Space Station (ISS), is to contribute to exploratory research and its applications in space medicine to enhance the safety of space explorers and utilize the knowledge gained for the benefit the patient community globally.

The scientific experiments lasted for four days and were overseen by the research team led by Dr. Khaled Saad Abu Khubrah, Head of the Department of Molecular Biomedicine and Research at KFSH&RC, along with Dr. Wijdan Al-Ahmadi from KFSH&RC and Dr. Edward Hattie from the BioServe Space Technologies Center in Colorado, USA.

KFSH&RC is actively pursuing further research in space biomedical science to gain a more comprehensive understanding of the effects of gravity deficiency and cosmic radiation on the human body. They aim to leverage the unique space environment, which provides opportunities for medical experiments that are not feasible on Earth. This includes studying how cells and tissues grow in microgravity conditions, potentially leading to groundbreaking discoveries in disease treatments and opening new avenues in space medicine.

KFSH&RC is globally renowned for its specialized healthcare services and its leadership in innovation. It stands as an advanced centre for medical research and education, aiming to advance medical technologies and raise the standard of healthcare worldwide through partnerships with prominent local, regional, and international institutions in clinical, research, and educational fields.

Contact information:
kfshrc@mcsaatchi.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/78eba5fa-19d6-437c-ab42-c9a09636e91e

https://www.globenewswire.com/NewsRoom/AttachmentNg/c30c198b-dd13-4d48-8b8c-6667eda49b45

Source: King Faisal Specialist Hospital & Research Centre

–BERNAMA